May 17, 2012 7:24 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Rosetta Genomics, Ltd. (NASDAQ: ROSG) yesterday announced it has entered into definitive agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share in a registered direct offering. The offering is expected to close on or about May 22, 2012, subject to the satisfaction of customary closing conditions. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.